Floatz logo

Dyne-251

Duchenne Muscular Dystrophy (DMD)

Dyne TherapeuticsPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

55 Active assets in the Duchenne Muscular Dystrophy (DMD) cohort.

Asset / SponsorPhaseRating
Viltolarsen
NS Pharma, Inc.
Phase 4BBB
Golodirsen
Rare Disease Research, LLC
Phase 4BB
Delandistrogene Moxeparvovec
Sarepta Therapeutics, Inc.
Phase 3BB
Aoc 1044
Avidity Biosciences, Inc.
Phase 3BB
Glutamine
Assistance Publique - Hôpitaux de Paris
Phase 3BB

View all 50 →

Same molecule, other indications

Dyne-251 is also rated in:

Muscular DystrophiesDormant
B
Indicative ·
60 / 100
View asset →
Muscular Dystrophy, Duchenne and Becker TypesDormant
B
Indicative ·
60 / 100
View asset →
Genetic Disease, InbornDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →